
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 10-Q

- QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended December 31, 2002

OR

- TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 [NO FEE REQUIRED]**

Commission file number 0-13801

QUALITY SYSTEMS, INC.
(Exact name of registrant as specified in its charter)

California
(State or Other Jurisdiction of
Incorporation or Organization)

95-2888568
(I.R.S. Employer
Identification No.)

18191 Von Karman Avenue, Irvine California
(Address of Principal Executive Offices)

92612
(Zip Code)

Registrant's telephone number, including area code: (949) 255-2600

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding twelve months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past ninety days. Yes No

Indicate the number of shares outstanding of each of the Registrant's classes of Common Stock as of the latest practicable date: 6,139,239 shares of Common Stock, \$.01 par value, as of February 12, 2003

PART I – CONSOLIDATED FINANCIAL INFORMATION

Item 1. *Financial Statements*

QUALITY SYSTEMS, INC. CONSOLIDATED BALANCE SHEETS

(in thousands)	<i>December 31, 2002 (unaudited)</i>	<i>March 31, 2002</i>
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 33,146	\$ 25,443
Short-term investments	-	255
Accounts receivable, net	16,488	13,695
Inventories, net	977	1,118
Deferred tax assets	1,368	1,368
Other current assets	1,105	1,013
Total current assets	53,084	42,892
Equipment and improvements, net	1,752	1,578
Capitalized software costs, net	2,226	2,103
Deferred tax assets	2,778	2,778
Goodwill, net	1,840	1,840
Other assets	804	952
Total assets	<u>\$ 62,484</u>	<u>\$ 52,143</u>
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 1,875	\$ 2,657
Deferred service revenue	9,739	6,155
Other current liabilities	5,291	3,281
Total liabilities	16,905	12,093
Commitments and contingencies	-	-
Shareholders' equity:		
Common stock, \$0.01 par value, 20,000 shares authorized, 6,138 and 6,105 shares issued and outstanding, respectively	61	61
Additional paid-in capital	34,931	34,674
Retained Earnings	10,587	5,315
Total shareholders' equity	45,579	40,050
Total liabilities and shareholders' equity	<u>\$ 62,484</u>	<u>\$ 52,143</u>

See notes to consolidated financial statements.

QUALITY SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)

(in thousands)

	<i>Three Months Ended December 31,</i>		<i>Nine Months Ended December 31,</i>	
	<i>2002</i>	<i>2001</i>	<i>2002</i>	<i>2001</i>
Net Revenues:				
Sales of computer systems, upgrades and supplies	\$ 7,666	\$ 5,458	\$ 20,905	\$ 16,162
Maintenance and other services	6,734	5,585	18,796	16,287
	14,400	11,043	39,701	32,449
Cost of Products and Services	6,353	4,900	16,933	14,181
Gross Profit	8,047	6,143	22,768	18,268
Selling, General and Administrative Expenses	3,918	3,017	11,033	9,556
Research and Development Costs	1,347	1,057	3,695	3,164
Income from Operations	2,782	2,069	8,040	5,548
Investment Income	109	147	336	543
Income before Provision for Income Taxes	2,891	2,216	8,376	6,091
Provision for Income Taxes	956	833	3,104	2,316
Net Income	\$ 1,935	\$ 1,383	\$ 5,272	\$ 3,775
Net Income per Share, basic	\$ 0.32	\$ 0.23	\$ 0.86	\$ 0.63
Net Income per Share, diluted	\$ 0.30	\$ 0.22	\$ 0.83	\$ 0.61

See notes to consolidated financial statements.

QUALITY SYSTEMS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

(in thousands)	<i>Nine Months Ended December 31,</i>	
	<i>2002</i>	<i>2001</i>
Cash Flows from Operating Activities:		
Net Income	\$ 5,272	\$ 3,775
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	1,622	1,556
Changes in:		
Accounts receivable	(2,793)	467
Inventories	141	258
Other current assets	(92)	(317)
Other assets	133	-
Accounts payable	(782)	(651)
Deferred service revenue	3,584	524
Other current liabilities	2,010	336
Net Cash Provided By Operating Activities	9,095	5,948
Cash Flows From Investing Activities:		
Proceeds from the sale of short term investments	255	--
Net additions to equipment and improvements	(859)	(327)
Additions to capitalized software costs	(1,045)	(1,056)
Net Cash Used In Investing Activities	(1,649)	(1,383)
Cash Flows from Financing Activities:		
Proceeds from exercise of stock options	257	361
Net Cash Provided by Financing Activities	257	361
Net Increase in Cash and Cash Equivalents	7,703	4,926
Cash and Cash Equivalents, beginning of period	25,443	18,471
Cash and Cash Equivalents, end of period	\$ 33,146	\$ 23,397

Supplemental Information – During the nine months ended December 31, 2002 and 2001, the Company made income tax payments, net of refunds received, of \$2,411,000 and \$2,028,000, respectively.

See notes to consolidated financial statements.

QUALITY SYSTEMS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

1. Basis of Presentation

The accompanying unaudited consolidated financial statements as of December 31, 2002 and for the three and nine month periods ended December 31, 2002 and 2001, have been prepared in accordance with the requirements of Form 10-Q and, therefore, do not include all information and footnotes which would be presented were such financial statements prepared in accordance with generally accepted accounting principles. These condensed financial statements should be read in conjunction with the audited consolidated financial statements presented in the Company's Annual Report on form 10-K for the fiscal year ended March 31, 2002. In the opinion of management, the accompanying consolidated financial statements reflect all adjustments which are necessary for a fair presentation of the results of operations and cash flows for the periods presented. The results of operations for such interim periods are not necessarily indicative of results of operations to be expected for the full year. Certain prior period amounts in the accompanying consolidated financial statements have been reclassified to conform with the December 31, 2002 presentation.

2. Recent Accounting Pronouncements

The Company has adopted Statement of Financial Accounting Standards No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets" (SFAS 144). SFAS 144 establishes a single accounting model for the Impairment or disposal of long-lived assets, including discontinued operations. SFAS 144 superseded Statement of Financial Accounting Standards No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of" (SFAS 121), and APB Opinion No. 30, Reporting the Results of Operations-Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions. The adoption of this statement did not have a material effect on the Company's consolidated financial statements.

In April 2002, the FASB issued FAS No. 145, "Rescission of FAS Statements No. 4, 44 and 64, Amendment of FAS Statement No. 13, and Technical Corrections," to update, clarify and simplify existing accounting pronouncements. FAS Statement No. 4, which required all gains and losses from debt extinguishment to be aggregated and, if material, classified as an extraordinary item, net of related tax effect, was rescinded. Consequently, FAS Statement No. 64, which amended FAS Statement No. 4, was rescinded because it was no longer necessary. The adoption of this statement did not have a material effect on the Company's consolidated financial statements.

In June 2002, the FASB issued Statement of Financial Accounting Standards No. 146 "Accounting for Costs Associated with Exit or Disposal Activities" (SFAS 146), which provides financial accounting and reporting guidance for costs associated with exit or disposal activities, including one-time termination benefits, contract termination costs other than for a capital lease, and costs to consolidate facilities or relocate employees. SFAS 146 nullifies EITF Issue 94-3, "Liability Recognition for Certain Employee Termination Benefits and Other Costs to Exit an Activity (including Certain Costs Incurred in a Restructuring).

Under SFAS 146, a liability for a cost associated with an exit or disposal activity should be recognized and measured initially at its fair value in the period in which the liability is incurred, except for a liability for one-time termination benefits that is incurred over time. Accounting for one-time benefits depends on whether the employee will be providing future services. In addition, a liability for costs to terminate a contract before the end of its term should be recognized and measured at its fair value at the time the entity terminates the contract in accordance with its terms. A liability for costs that will continue to be incurred under the contract for its remaining term without economic benefit to the entity should be recognized and measured at its fair value when the entity ceases to use the right conveyed by the contract.

SFAS 146 is effective for exit or disposal activities initiated after December 31, 2002. The Company has not determined the impact the adoption of SFAS 146 will have on its consolidated financial position or results of operations.

3. Intangible Assets

The Company adopted Financial Accounting Standards Board No. 142 “Goodwill and Other Intangible Assets” (“FASB 142”) effective April 1, 2001. In accordance with FASB 142, the Company does not amortize goodwill. The balance of goodwill is related to the Company’s NextGen Healthcare Information Systems (NextGen) Division. In accordance with FASB 142, the Company has compared the fair value of the NextGen Division with the carrying amount of assets associated with the Division and determined that none of the goodwill recorded as of June 30, 2002 was impaired. The fair value of the NextGen Division was determined using an estimate of future cash flows of the Division and a risk adjusted discount rate to compute a net present value of future cash flows.

As of December 31, 2002, the Company had the following amounts related to intangible assets:

(in thousands)	<i>Gross Carrying Amount</i>	<i>Accumulated Amortization</i>	<i>Net Intangible Assets</i>
Capitalized software development (3 yrs)	\$ 7,408	\$(5,182)	\$ 2,226
Aggregate amortization expense for the nine months ended December 31, 2002			\$ 922

The unamortized balance of capitalized software development costs is estimated to be amortized as follows:

<i>For the year ending March 31,</i>	<i>Estimated Amortization Expense (in thousands)</i>
2003 (fourth quarter only)	\$ 322
2004	\$ 1,059
2005	\$ 668
2006	\$ 177

4. Stock Repurchase Plan

In October 2001, the Company’s Board of Directors authorized the repurchase on the open market of up to 5% of the shares of the Company’s outstanding Common stock, subject to compliance with applicable laws and regulations. There is no requirement that the Company repurchase such shares. This stock repurchase authorization expires on the date of the fiscal 2003 Annual Shareholders Meeting. Since the October 2001 authorization through December 31, 2002, no shares have been repurchased.

5. Income Taxes

During the quarter ended December 31, 2002, the Company filed amended federal and state tax returns for the fiscal years ended March 31, 1998 through 2002 to take advantage of available tax credits related to the Company’s research and development activities. The tax credits reported on the aforementioned returns were approximately \$668,000 for federal and \$266,000 for state income tax purposes. These tax credits have not yet been recorded in the income tax provision of the Company’s financial statements. The provision for income tax for the quarter ended December 31, 2002 reflects estimated fiscal 2003 year-to-date research and development tax credits. Tax credits relating to previous fiscal years which have

not yet been recorded will be recorded at the earlier of the amended returns having been audited or the statute of limitations running out on the amended returns (November, 2006 for the federal returns and November, 2007 for the state returns). Due to the uncertainty concerning the ultimate amount to be refunded, management has recorded a valuation allowance for the full amount of the tax credit.

The provision for income taxes for the three and nine month periods ended December 31, 2002 differ from the expected combined statutory rates primarily due to the estimated impact of varying state income tax rates, as well as research and development tax credits for fiscal 2003. The provision for income taxes for the three and nine month periods ended December 31, 2001 differs from the expected combined statutory rates primarily due to the estimated impact of varying state income tax rates.

6. Net Income Per Share

The following table reconciles the weighted average shares outstanding for basic and diluted net income per share for the periods indicated. Basic net income per share is based upon the weighted average number of common shares outstanding. Diluted net income per share is based on the assumption that the Company's outstanding options are included in the calculation of diluted earnings per share, except when their effect would be anti-dilutive. Dilution is computed by applying the treasury stock method. Under this method, options are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period.

(in thousands, except per share amounts)

	<i>Three Months Ended December 31,</i>		<i>Nine Months Ended December 31,</i>	
	<i>2002</i>	<i>2001</i>	<i>2002</i>	<i>2001</i>
Net income	\$ 1,935	\$ 1,383	\$ 5,272	\$ 3,775
Basic net income per common share:				
Weighted average of common shares outstanding	6,134	6,026	6,121	6,007
Basic net income per common share	\$ 0.32	\$ 0.23	\$ 0.86	\$ 0.63
Diluted net income per common share:				
Weighted average of common shares outstanding	6,134	6,026	6,121	6,007
Effect of potentially dilutive securities (options)	269	198	242	184
Weighted average number of common shares – Diluted	6,403	6,224	6,363	6,191
Diluted net income per common share	\$ 0.30	\$ 0.22	\$ 0.83	\$ 0.61

7. Operating Segment Information

The Company has prepared operating segment information in accordance with Statement of Accounting Standards (“SFAS”) No. 131 “Disclosures About Segments of an Enterprise and Related Information” (“SFAS No. 131”) to report components that are evaluated regularly by the Company's chief operating decision maker, or decision making group in deciding how to allocate resources and in assessing performance.

The Company's reportable operating segments include its NextGen Healthcare Information Systems Division and the QSI Division. The Company's NextGen Healthcare Information Systems division sells proprietary electronic medical records software and practice management systems under the NextGen^{®1} product name. The QSI division develops and markets dental and medical practice management software

¹ NextGen is a registered trademark of NextGen Healthcare Information Systems, Inc.

suites utilizing a UNIX² operating system. Both divisions also market electronic connectivity services to their respective client basis.

The disaggregated financial results of the segments reflect allocation of certain functional expense categories consistent with the basis and manner in which Company management internally disaggregates financial information for the purpose of assisting in making internal operating decisions. Certain corporate overhead costs are not allocated to the individual segments by management. The Company evaluates performance based on stand-alone segment operating income. Because the Company does not evaluate performance based on return on assets at the operating segment level, assets are not tracked internally by segment. Therefore, segment asset information is not presented.

Operating segment data for the three and nine month periods ended December 31, 2002 and 2001 is as follows:

(in thousands)

	<i>QSI Division</i>	<i>NextGen Healthcare Information Systems Division</i>	<i>Unallocated Corporate Expenses</i>	<i>Consolidated</i>
Nine Months Ended December 31, 2002				
Revenue	\$ 13,036	\$ 26,665	-	\$ 39,701
Operating income (loss)	\$ 3,642	\$ 6,470	\$ (2,072)	\$ 8,040
Nine Months Ended December 31, 2001				
Revenue	\$ 12,918	\$ 19,531	--	\$ 32,449
Operating Income (Loss)	\$ 3,906	\$ 3,125	\$ (1,483)	\$ 5,548
Three Months Ended December 31, 2002				
Revenue	\$ 4,404	\$ 9,996	-	\$ 14,400
Operating Income (Loss)	\$ 1,340	\$ 2,259	\$ (817)	\$ 2,782
Three Months Ended December 31, 2001				
Revenue	\$ 4,372	\$ 6,671	--	\$ 11,043
Operating Income (Loss)	\$ 1,417	\$ 1,166	\$ (514)	\$ 2,069

8. Composition of Accounts Receivable

Included in accounts receivable are amounts related to maintenance and services which were billed but not yet rendered as of the end of the period. Undelivered maintenance and services are included on the consolidated balance sheet as part of the deferred revenue balance.

(in thousands)

	<i>December 31, 2002 (unaudited)</i>	<i>March 31, 2002</i>
ACCOUNTS RECEIVABLE:		
Accounts receivable, net of reserve for bad debts, excluding undelivered maintenance and services	\$ 12,004	\$ 10,403
Undelivered maintenance and services billed in advance, included in deferred revenue (estimated)	\$ 4,484	3,292
Net accounts receivable	\$ 16,488	\$ 13,695

² UNIX is a registered trademark of The Open Group in the United States and other countries.

9. Concentration of Credit Risk

The Company has cash deposits at U.S. banks and financial institutions, which exceed federally insured limits at December 31, 2002. The Company is exposed to credit loss for amounts in excess of insured limits in the event of non-performance by the institution; however, the Company does not anticipate non-performance.

Item 2. *Management's Discussion and Analysis of Financial Condition and Results of Operations.*

Except for the historical information contained herein, the matters discussed in this Quarterly Report on Form 10-Q, including discussions of the Company's product development plans, business strategies and market factors influencing the Company's results, are forward-looking statements that involve certain risks and uncertainties. Actual results may differ from those anticipated by the Company as a result of various factors, both foreseen and unforeseen, including, but not limited to, the Company's ability to continue to develop new products and increase systems sales in markets characterized by rapid technological evolution, consolidation within the Company's target marketplace and among the Company's competitors, and competition from larger, better capitalized competitors. Many other economic, competitive, governmental and technological factors could impact the Company's ability to achieve its goals. Interested persons are urged to review the risks described below, as well as in the Company's other public disclosures and filings with the Securities and Exchange Commission.

Company Overview

Quality Systems, Inc., through its NextGen Healthcare Information Systems, Inc. (NextGen³) and QSI (QSI) divisions (collectively, the "Company"), develops and markets healthcare information systems that automate medical and dental group practices, physician hospital organizations ("PHOs"), management service organizations ("MSOs"), ambulatory care centers, community health centers, and medical and dental schools. In response to the growing need for more comprehensive, cost-effective information solutions for medical and dental practices, the Company's systems allow clients the opportunity to redesign office workflow processes, improve productivity, reduce information processing and administrative costs, and utilize electronic medical records to store and access patient information. The Company's proprietary software systems cover a number of important practice elements including, but not limited to, general patient information, electronic patient records, appointment scheduling, billing, insurance claims submission and processing, eligibility verification, managed care plan implementation, referral management, treatment outcome studies, treatment planning, drug formularies, dental charting, and letter generation. Several of the Company's software systems may be operated remotely using thin client connectivity or a standard web browser. In addition to providing fully integrated software solutions to its clients, the Company offers comprehensive hardware and software installation services, maintenance and support services, and system training services.

The Company currently has a base of approximately 850 clients, with each client generally including between one and 500 physicians or dentists. The Company believes that as healthcare providers are increasingly required to reduce costs and maintain the quality of healthcare, the Company will be able to capitalize on its strategy of providing fully integrated information systems and superior client service.

The Company, a California corporation formed in 1974, was founded with an early focus on providing information systems and services for dental group practices. In the mid-1980's, the Company capitalized on the increasing focus on medical cost containment and further expanded its information processing systems to serve the medical market. Today, the Company has dedicated products serving both the medical and dental markets.

³ The Company's NextGen Division, formerly known as "MicroMed Healthcare Information Systems" or "MicroMed Division", changed its name in fiscal 2002.

The Company's QSI Division develops and markets dental practice management and medical practice management software suites utilizing a UNIX⁴ operating system. Its Clinical Product Suite ("CPS") utilizes a Windows NT⁵ operating system and can be fully integrated with the Company's dental practice management applications. CPS incorporates a wide range of clinical tools including, but not limited to, periodontal charting and digital imaging of X-ray and inter-oral camera images as part of an electronic patient record. In addition, the QSI Division develops and markets the Company's QUIC and NextGen edi product suite which incorporates a variety of products that enhance the connectivity between provider and payor, and provider and patient. The QSINet Application Service Provider ("ASP")/Internet product offering is also developed and marketed in this Division. QSINet enables providers to extend patient appointment scheduling, electronic bill payment, and other functions to patients via the Internet.

The Company's NextGen Healthcare Information Systems, Inc. Division develops and sells proprietary electronic medical records software and practice management systems under the NextGen[®] product name. Major product categories of the NextGen suite include Electronic Medical Records (NextGen^{emr}), Enterprise Practice Management (NextGen^{epm}), Enterprise Appointment Scheduling (NextGen ^{eas}), Enterprise Master Patient Index (NextGen^{epi}), Managed Care, Electronic Data Interchange, System Interfaces, Internet Operability (NextGen^{web}), a patient-centric and provider-centric Web portal solution (NextMD.com⁶), and a handheld product (NextGen^{pda}). The Company's enterprise practice management and electronic medical records software packages can run via private intranet or via the Internet in an ASP environment.

Enhancements to these products continued during the quarter.

Risk Factors

Competition. The markets for healthcare information systems are intensely competitive, and the Company faces significant competition from a number of different sources. Several of the Company's competitors have significantly greater name recognition as well as substantially greater financial, technical, product development and marketing resources than the Company.

The Company competes in all of its markets with other major healthcare related companies, information management companies, systems integrators, and other software developers. Competitive pressures and other factors, such as new product introductions by the Company or its competitors, may result in price or market share erosion that could have a material adverse effect on the Company's business, results of operations and financial condition. Also, there can be no assurance that the Company's applications will achieve broad market acceptance or will successfully compete with other competing software products.

The Company's inability to make initial sales of its systems to either newly formed groups and/or healthcare providers that are replacing or substantially modifying their healthcare information systems could have a material adverse effect on the Company's business, results of operations and financial condition. If new systems sales do not materialize, the Company's maintenance revenues can be expected to decrease over time due to the combined effects of potential attrition of existing clients and a shortfall in new client additions.

Fluctuation in Quarterly Operating Results. The Company's revenues and operating results have fluctuated in the past, and may fluctuate in the future from quarter to quarter and period to period, as a result of a number of factors including, without limitation: the size and timing of orders from clients; the length of sales cycles and installation processes; the ability of the Company's clients to obtain financing for the purchase of the Company's products; changes in pricing policies or price reductions by the Company or its competitors; the timing of new product announcements and product introductions by the Company or its competitors; the availability and cost of system components; the financial stability of

⁴ UNIX is a registered trademark of The Open Group in the United States and other countries.

⁵ Microsoft Windows, Windows NT, Windows 95, Windows 98, and Windows 2000 are registered trademarks of Microsoft Corporation.

⁶ NextMD.com is a trademark of NextGen Healthcare Information Systems, Inc.

major clients; market acceptance of new products, applications and product enhancements; the Company's ability to develop, introduce and market new products, applications and product enhancements and to control costs; the Company's success in expanding its sales and marketing programs; deferrals of client orders in anticipation of new products, applications or product enhancements; changes in Company strategy; personnel changes; and general governmental and economic factors.

The Company's products are generally shipped as orders are received and accordingly, the Company has historically operated with minimal backlog. As a result, sales in any quarter are dependent on orders booked and shipped in that quarter and are not predictable with any degree of certainty. Further, the Company's systems can be relatively large and expensive and individual systems sales can represent a significant portion of the Company's revenues for a quarter such that the loss or deferral of even one such sale can have a significant adverse impact on the Company's quarterly profitability.

Clients often defer systems purchases until the Company's quarter end, so quarterly results generally cannot be predicted and frequently are not known until the quarter has concluded.

The Company's sales are dependent upon a client's initial decision to replace, or substantially modify its existing information system, and subsequently a decision as to which products and services to purchase. These are major decisions for healthcare providers, and accordingly, the sales cycle for the Company's systems can vary significantly and typically ranges from three to twelve months from initial contact to contract execution/shipment.

Because a significant percentage of the Company's expenses are relatively fixed, a variation in the timing of systems sales and installations can cause significant variations in operating results from quarter to quarter. As a result, the Company believes that interim period-to-period comparisons of its results of operations are not necessarily meaningful and should not be relied upon as indications of future performance. Further, the Company's historical operating results are not necessarily indicative of future performance for any particular period.

The Company recognizes revenue pursuant to Statement of Position ("SOP") No. 97-2, "Software Revenue Recognition" ("SOP 97-2"). Additionally, in December 1999, the Securities and Exchange Commission ("SEC") issued Staff Accounting Bulletin No. 101, "Revenue Recognition in Financial Statements" ("SAB 101"). SAB 101 summarizes the staff's views in applying generally accepted accounting principles to revenue recognition in financial statements. SAB 101 became effective for the Company in the third quarter of fiscal 2001.

There can be no assurance that the application and subsequent interpretation of these pronouncements will not further modify the Company's revenue recognition policies, or that such modifications would not have a material adverse effect on the operating results reported in any particular quarter.

There can be no assurance that the Company will not be required to adopt changes in its licensing or services practices to conform to SOP 97-2 or SAB 101, or that such changes, if adopted, would not result in delays or cancellations of potential sales of the Company's products.

Due to all of the foregoing factors, it is possible that in some future quarter(s) the Company's operating results may be below the expectations of public market analysts and investors. In such event, the price of the Company's Common Stock would likely be materially adversely affected.

Dependence on Principal Product and New Product Development. The Company currently derives substantially all of its net revenues from sales of its healthcare information systems and related services. The Company believes that a primary factor in the market acceptance of its systems has been its ability to meet the needs of users of healthcare information systems. The Company's future financial performance will depend in large part on the Company's ability to continue to meet the increasingly sophisticated needs of its clients through the timely development, successful introduction and implementation of new and enhanced versions of its systems and other complementary products. The Company has historically expended a significant percentage of its net revenues on product development and believes that significant continuing product development efforts will be required to sustain the Company's growth.

There can be no assurance that the Company will be successful in its product development efforts, that the market will continue to accept the Company's existing products, or that new products or product enhancements will be developed and implemented in a timely manner, meet the requirements of healthcare providers, or achieve market acceptance. If new products or product enhancements do not achieve market acceptance, the Company's business, results of operations and financial condition could be materially adversely affected. At certain times in the past, the Company has also experienced delays in purchases of its products by clients anticipating the launch of new products by the Company. There can be no assurance that material order deferrals in anticipation of new product introductions will not occur.

Technological Change. The software market generally is characterized by rapid technological change, changing customer needs, frequent new product introductions, and evolving industry standards. The introduction of products incorporating new technologies and the emergence of new industry standards could render the Company's existing products obsolete and unmarketable. There can be no assurance that the Company will be successful in developing and marketing new products that respond to technological changes or evolving industry standards. New product development depends upon significant research and development expenditures which depend ultimately upon sales growth. Any material weakness in revenues or research funding could impair the Company's ability to respond to technological advances in the marketplace and to remain competitive. If the Company is unable, for technological or other reasons, to develop and introduce new products in a timely manner in response to changing market conditions or customer requirements, the Company's business, results of operations and financial condition may be materially adversely affected.

In response to increasing market demand, the Company is currently developing new generations of certain of its software products. There can be no assurance that the Company will successfully develop these new software products or that these products will operate successfully, or that any such development, even if successful, will be completed concurrently with or prior to introduction of competing products. Any such failure or delay could adversely affect the Company's competitive position and/or could make the Company's current products obsolete.

Litigation. The Company faces one private Federal securities litigation action (see "Part II – Other Information, Item 1. Legal Proceedings."). At this time it is not reasonably possible to estimate the damage, or the range of damages, if any, that the Company might incur in connection with these actions. However, the uncertainty associated with substantial unresolved litigation may have an adverse impact on the Company's business. In particular, such litigation could impair the Company's relationships with existing customers and its ability to obtain new customers. Defending such litigation may result in a diversion of management's time and attention away from business operations, which could have a material adverse effect on the Company's business, results of operations and financial condition. Such litigation may also have the effect of discouraging potential acquirers from bidding for the Company or reducing the consideration such acquirers would otherwise be willing to pay in connection with an acquisition.

There can be no assurance that such litigation will not result in liability in excess of the Company's insurance coverage, that the Company's insurance will cover such claims or that appropriate insurance will continue to be available to the Company in the future at commercially reasonable rates.

Proprietary Technology. The Company is heavily dependent on the maintenance and protection of its intellectual property and relies largely on license agreements, confidentiality procedures, and employee nondisclosure agreements to protect its intellectual property. The Company's software is not patented and the Company believes that existing copyright laws offer only limited practical protection.

There can be no assurance that the legal protections and precautions taken by the Company will be adequate to prevent misappropriation of the Company's technology or that competitors will not independently develop technologies equivalent or superior to the Company's. Further, the laws of some foreign countries do not protect the Company's proprietary rights to as great an extent as do the laws of the United States and are often not enforced as vigorously as those in the United States.

The Company does not believe that its operations or products infringe on the intellectual property rights of others. However, there can be no assurance that others will not assert infringement or trade secret claims against the Company with respect to its current or future products or that any such assertion will not require the Company to enter into a license agreement or royalty arrangement with the party asserting the claim. As competing healthcare information systems increase in complexity and overall capabilities and the functionality of these systems further overlaps, providers of such systems may become increasingly subject to infringement claims. Responding to and defending any such claims may distract the attention of Company management and have a material adverse effect on the Company's business, results of operations and financial condition. In addition, claims may be brought against third parties from which the Company purchases software, and such claims could adversely affect the Company's ability to access third party software for its systems.

Ability to Manage Growth. The Company has in the past experienced periods of growth which have placed, and may continue to place, a significant strain on the Company's non-cash resources. The Company also anticipates expanding its overall software development, marketing, sales, support, and customer service and training capacity. In the event the Company is unable to identify, hire, train and retain qualified individuals in such capacities within a reasonable timeframe, such failure could have a material adverse effect on the Company. In addition, the Company's ability to manage future increases, if any, in the scope of its operations or personnel will depend on significant expansion of its research and development, marketing and sales, management, and administrative and financial capabilities. The failure of the Company's management to effectively manage expansion in its business could have a material adverse effect on the Company's business, results of operations and financial condition.

Dependence Upon Key Personnel. The Company's future performance also depends in significant part upon the continued service of its key technical and senior management personnel, many of whom have been with the Company for a significant period of time. The Company does not maintain key man life insurance on any of its employees. Because the Company has a relatively small number of employees when compared to other leading companies in the same industry, its dependence on retaining its employees is particularly significant. The Company is also dependent on its ability to attract high quality personnel, particularly in the areas of sales and applications development.

The industry in which the Company operates is characterized by a high level of employee mobility and aggressive recruiting of skilled personnel. There can be no assurance that the Company's current employees will continue to work for the Company.

The loss of the services of key employees could have a material adverse effect on the Company's business, results of operations and financial condition. Furthermore, the Company may need to grant additional stock options to key employees and provide other forms of incentive compensation to attract and retain such key personnel.

Product Liability. Certain of the Company's products provide applications that relate to patient clinical information. Any failure by the Company's products to provide accurate and timely information could result in claims against the Company. In addition, a court or government agency may take the position that the Company's delivery of health information directly, including through licensed practitioners, or delivery of information by a third party site that a consumer accesses through the Company's web sites, exposes the Company to malpractice or other personal injury liability for wrongful delivery of healthcare services or erroneous health information. The Company maintains insurance to protect against claims associated with the use of its products and services, but there can be no assurance that its insurance coverage would adequately cover any claim asserted against the Company. A successful claim brought against the Company in excess of its insurance coverage could have a material adverse effect on the Company's business, results of operations and financial condition. Even unsuccessful claims could result in the Company's expenditure of funds in litigation and management time and resources.

There can be no assurance that the Company will not be subject to product liability claims, that such claims will not result in liability in excess of its insurance coverage, that the Company's insurance will cover such claims or that appropriate insurance will continue to be available to the Company in the future

at commercially reasonable rates. Such claims could have a material adverse affect on the Company's business, results of operations and financial condition.

Uncertainty in Healthcare Industry; Government Regulation. The healthcare industry is subject to changing political, economic and regulatory influences, which have been increasing over the past several years. This increase has the potential to heighten governmental involvement in healthcare, lower reimbursement rates and otherwise change the operating environment for the Company's clients.

Healthcare providers may react to current proposals as well as the uncertainty surrounding future proposals by curtailing or deferring investments, including investments in the kinds of systems and services offered by the Company. Additionally, cost-containment measures instituted by healthcare providers and payors as a result of regulatory reform or otherwise could result in a reduction in the availability of capital funds, and such a reduction could have an adverse effect on the Company's ability to sell its systems and related services. Conversely, changes in the regulatory environment can serve to increase the needs of healthcare organizations for cost-effective data management and thereby enhance the overall market for healthcare management information systems. The Company cannot predict what impact, if any, such proposals or healthcare reforms might have on the Company's business, financial condition and results of operations.

Numerous federal and state laws and regulations, the common law, and certain contractual obligations govern collection, dissemination, use and confidentiality of protected health information (which includes individually identifiable health information) , including but not limited to:

- State privacy and confidentiality laws;
- The Company's contracts with customers and partners;
- State laws regulating healthcare professionals;
- Medicaid laws; and
- Requirements of the Health Insurance Portability and Accountability Act (HIPAA) of 1996 (note: while a number of HIPAA elements have been finalized, portions of the legislation remain to be finalized, and there exists no definitive timeline as to when these pending items will be resolved).

Any failure by the Company or by its personnel or partners to comply with applicable elements of these or other requirements may result in a material liability to the Company.

Although the Company has systems in place for safeguarding applicable patient health information from unauthorized disclosure which the company believes are adequate, these systems may not preclude claims against the Company for violation of applicable law or other requirements. Other third party sites or links that consumers access through the Company's web sites also may not maintain systems to safeguard this protected health information, or may circumvent systems the Company put in place to protect the protected health information from disclosure. In addition, future laws or changes in current laws may necessitate costly adaptations to the Company's systems.

HIPAA mandates the satisfaction of national standards when electronically transmitting certain patient healthcare information, and prescribes administrative, operational, and security measures to protect the confidentiality of patient's protected health information. These proposed and finalized regulations establish new federal standards for the security and privacy of health information. The Company anticipates that these regulations may directly affect the Company's products and services, but the Company cannot fully predict the impact at this time. While HIPAA compliance requires the client to implement technological and non-technological solutions, the Company's intention is to assist in providing tools and technologies that facilitate client compliance with the final regulations, but there can be no assurance that the Company will be able to do so in a timely manner. Achieving compliance with applicable regulations could be costly and distract management's attention and other resources from the Company's historical business, and any noncompliance by the Company could result in civil and criminal penalties. In addition, development of related Federal and state regulations and policies on confidentiality of health information could negatively affect the Company's business.

In addition, the Company's software may be subject to regulation by the U.S. Food and Drug Administration (the "FDA") as a medical device. Such regulation could require the registration of the

applicable manufacturing facility and software and hardware products, application of detailed record-keeping and manufacturing standards, and FDA approval or clearance prior to marketing. An approval or clearance requirement could create delays in marketing, and the FDA could require supplemental filings or object to certain of these applications, the result of which could have a material adverse effect on the Company's business, financial condition and results of operations.

Critical Accounting Policies

The discussion and analysis of the Company's financial condition and results of operations is based upon the Company's consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. On an on-going basis, management evaluates estimates, including those related to revenue recognition, uncollectible accounts receivables, and intangible assets, for reasonableness. Management bases its estimates on historical experience and on various other assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

The Company believes revenue recognition, the allowance for doubtful accounts, and goodwill impairment are among the most critical accounting policies that impact its consolidated financial statements.

Revenue Recognition. The Company's revenues are primarily generated from the sale of software licenses, maintenance fees, and electronic data interchange services. Revenue recognition is governed by Statement of Position 97-2, "Software Revenue Recognition" ("SOP 97-2"). Per SOP 97-2, if the arrangement does not require significant production, modification, or customization of software, revenue should be recognized when all of the following criteria are met:

- persuasive evidence of an arrangement exists;
- delivery has occurred;
- the vendor's fee is fixed or determinable; and
- collectibility is probable.

In accordance with generally accepted accounting principles in the United States of America, the recognition of software license revenues is based on management's assessment that the above criteria have been met. In general, the first two criteria are met with a signed contract and evidence that the Company has shipped its software to the customer. In those cases where undelivered elements of a system sale exists, the Company defers revenue related to the undelivered element based on vendor specific objective evidence of each element's fair value. Discounts for individual elements are aggregated, and the total discount is allocated back to the individual elements in its proportion of fair value to the total contract fair value. The Company determines that the fee is fixed or determinable based on the contract terms, which specify payment terms tied to dates and not to any future deliverables. Probability of collection is based on a credit review of new customers. The timing or amount of revenue recognition may have been different if different assessments of the above criteria had been made at the time transactions were recorded in revenue.

Valuation Allowances. The Company maintains allowances for doubtful accounts for estimated losses resulting from the inability of customers to make required payments. The valuation allowance is composed of both specific and general allowances. Management reviews customer accounts to determine specific valuation allowances for individual accounts and also sets general valuation allowances based on the aging of customer accounts. If the financial condition of customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required.

Goodwill Impairment. The Company's long-lived assets include goodwill of \$1.8 million as of December 31, 2002 and 2001, respectively. The Company adopted SFAS No. 142 "Goodwill and Other Intangible Assets" ("SFAS 142") effective April 1, 2001. The statement applies to the amortization of

goodwill and other intangible assets. The Company has ceased amortizing amounts related to goodwill effective April 1, 2001. The balance of goodwill is related to the Company's NextGen Division. The Company has compared the fair value of the NextGen Division with the carrying amount of assets associated with the Division and determined that none of the goodwill recorded as of June 30, 2002 was impaired. The fair value of the NextGen Division was determined using a reasonable estimate of future cash flows of the Division and a risk adjusted discount rate to compute a net present value of future cash flows.

The process of evaluating goodwill for impairment involves the determination of the fair value of the relevant Company business segments. Inherent in such fair value determinations are certain judgments and estimates, including the interpretation of current economic indicators and market valuations, and assumptions about the Company's strategic plans with regard to operations. To the extent additional information arises or the strategies of the Company change, it is possible that the Company's conclusion regarding goodwill impairment could change and result in a material effect on its financial position or results of operations.

Results of Operations

The following table sets forth for the periods indicated, the percentage of net revenues represented by each item in the Company's Consolidated Statements of Income.

	<i>Three Months Ended December 31,</i>		<i>Nine Months Ended December 31,</i>	
	<i>2002 (unaudited)</i>	<i>2001 (unaudited)</i>	<i>2002 (unaudited)</i>	<i>2001 (unaudited)</i>
Net Revenues:				
Sales of computer systems, upgrades and supplies	53.2%	49.4%	52.7%	49.8%
Maintenance and other services	46.8	50.6	47.3	50.2
	100.0	100.0	100.0	100.0
Cost of Products and Services	44.1	44.4	42.7	43.7
Gross Profit	55.9	55.6	57.3	56.3
Selling, General and Administrative Expenses	27.2	27.3	27.8	29.4
Research and Development Costs	9.4	9.6	9.3	9.8
Income from Operations	19.3	18.7	20.3	17.1
Investment Income	0.8	1.3	0.8	1.7
Income before Provision for Income Taxes	20.1	20.0	21.1	18.8
Provision for Income Taxes	6.6	7.5	7.8	7.2
Net Income	13.5%	12.5%	13.3%	11.6%

For the Three-Month Periods Ended December 31, 2002 and 2001

The Company's net income for the three months ended December 31, 2002 was \$1,935,000 or \$0.32 per share on a basic and \$0.30 per share on a diluted basis, as compared to net income of \$1,383,000, or \$0.23 per share on a basic and \$0.22 on a diluted basis, for the three months ended December 31, 2001.

Net Revenues. Net revenues for the three months ended December 31, 2002 increased 31% to \$14.4 million from \$11.0 million for the three months ended December 31, 2001. Sales of computer systems, upgrades and supplies increased 40% to \$7.7 million from \$5.5 million while revenues from maintenance and other services grew 20% to \$6.7 million from \$5.6 million during the comparable period. The increase in revenues from sales of computer systems, upgrades and supplies was principally the result of an increase in license, hardware, third party software, and services revenue related to systems sales at the Company's NextGen Division. The increase in maintenance and other services revenue resulted principally from an increase in maintenance and EDI revenues generated from the Company's expanded NextGen client base.

Cost of Products and Services. Cost of products and services for the three months ended December 31, 2002 rose 31% to \$6.4 million from \$4.9 million in the prior year quarter. Cost of products and services as a percentage of net revenues decreased to 44.1% from 44.4%. The dollar increase in the cost of products and services was primarily the result of a higher volume of hardware associated with increased volume of NextGen^{emr} and NextGen^{epm} license sales as well as the impact of higher labor costs associated with installation, training, and support. The cost of products and services as a percentage of net revenues decreased slightly in the quarter ended December 31, 2002, largely as a result of a decrease in the relative hardware component of systems sales revenues.

Selling, General and Administrative Expenses. Selling, general and administrative expenses for the three months ended December 31, 2002 increased approximately 30% to approximately \$3.9 million as compared to \$3.0 million for the three months ended December 31, 2001. Selling, general and administrative expenses as a percentage of net revenues was roughly unchanged at 27.2% as compared to 27.3% in the year earlier quarter. The increase in the dollar amount of such expenses resulted primarily from increased staffing and compensation expenses, as well as increased sales and marketing expenses at the Company's NextGen Division.

Research and Development Costs. Research and development costs for the three months ended December 31, 2002 increased by 27% to \$1,347,000 from \$1,057,000 in the prior year's quarter. The increase in research and development costs is attributed primarily to increased investments in the NextGen product suites. Research and development costs as a percentage of net revenues declined to 9.4% as compared to 9.6% for the quarter ended December 31, 2001. This decline was driven by the fact that revenues grew faster than the increase in research and development expense. The Company has, over time, changed the mix of its overall research and development expenditures to increase funds available for the NextGen Division while correspondingly decreasing the level of expenditure at its QSI Division. This has facilitated increased research and development spending at the NextGen Division while moderating the overall growth rate of research and development costs.

Investment Income. Investment income for the three months ended December 31, 2002 decreased by 26% to approximately \$109,000 compared to \$147,000 for the three months ended December 31, 2001. Investment income in the quarter declined due to the lower interest rates earned on the Company's balances during the quarter vis a vis the year earlier quarter. The decrease in interest income was partially offset by higher cash balances.

Provision for Income Taxes. The provision for income taxes for the three months ended December 31, 2002 was approximately \$956,000 as compared to approximately \$833,000 for the three months ended December 31, 2001. The provision for income taxes for the three months ended December 31, 2002 and 2001 differs from the combined statutory rates primarily due to the impact of varying state income tax rates. The provision for income taxes for the three month period ended December 31, 2002 also includes the application of the estimated year to date tax credits associated with research and development activities of the Company.

For the Nine-Month Periods Ended December 31, 2002 and 2001

The Company's net income for the nine months ended December 31, 2002 was \$5.3 million, or \$0.86 per share on a basic and \$0.83 per share on a diluted basis, as compared to \$3.8 million, or \$0.63 per share on a basic and \$0.61 per share on a diluted basis for the nine months ended December 31, 2001.

Net Revenues Net revenues for the nine months ended December 31, 2002 increased 23% to \$39.7 million from \$32.4 million for the nine months ended December 31, 2001. Sales of computer systems, upgrades and supplies increased 29% to \$20.9 million from \$16.2 million while revenues from maintenance and other services grew 15% to \$18.8 million from \$16.3 million during the comparable period. The increase in revenues from sales of computer systems, upgrades and supplies was principally the result of increases in the sales at the Company's NextGen Division. The \$2.5 million dollar increase in maintenance and other services revenue resulted principally from an increase in maintenance and EDI revenues from the NextGen division's growing client base.

Cost of Products and Services. Cost of products and services for the nine months ended December 31, 2002 increased 19% to \$16.9 million from \$14.2 million for the nine months ended December 31, 2001 while cost of products and services as a percentage of net revenues decreased to 42.7% from 43.7% during the comparable periods. The cost of products and services as a percentage of net revenues decreased primarily as a result of the impact of a change in the relative mix of hardware content of systems sales slightly offset by higher labor costs. The mix of hardware content included in systems sales each quarter varies from period to period. Because gross margins from hardware are significantly lower than margins achieved from software sales, the hardware content each quarter influences the gross margins of the company either higher or lower.

Selling, General and Administrative Expenses Selling, general and administrative expenses for the nine months ended December 31, 2002 increased 15% to \$11.0 million as compared to \$9.6 million for the nine months ended December 31, 2001. Selling, general and administrative expenses as a percentage of net revenues decreased to 27.8% from 29.4% in the year earlier period. The increase in the dollar amount of such expenses resulted primarily from additions to sales personnel, related increased commission expenses, and higher corporate expenses.

Research and Development Costs Research and development costs for the nine months ended December 31, 2002 and 2001 were \$3.7 million and \$3.2 million respectively. Research and development costs as a percentage of net revenues decreased to 9.3% from 9.8% due to the fact that revenues increased more quickly than R&D expense in the respective periods.

Investment Income. Investment income for the nine months ended December 31, 2002 was down 38% at approximately \$336,000 compared to \$543,000 in the nine months ended December 31, 2001. Investment income in the nine months ended December 31, 2002 declined primarily due to the effect of a drop in short term interest rates which occurred during the period. This was partially offset by higher cash balances.

Provision for Income Taxes. The provision for income taxes for the nine months ended December 31, 2002 was approximately \$3.1 million as compared to approximately \$2.3 million for the nine months ended December 31, 2001. The provision for income taxes for the nine month period ended December 31, 2002 differs from the combined statutory rates primarily due to the impact of varying state income tax rates, as well as tax credits associated with research and development activities of the Company occurring during fiscal 2003. The provision for income taxes for the nine month period ended December 31, 2001 differs from the combined statutory rates primarily due to the impact of varying state income tax rates.

Liquidity and Capital Resources

The following table presents selected financial statistics and information for the past nine months ended December 31, 2002 and 2001 (unaudited):

<i>(in thousands)</i>	<i>Nine Months Ended December 31,</i>	
	<i>2002</i>	<i>2001</i>
Cash and cash equivalents at end of period	\$33,146	\$23,397
Net increase in cash and cash equivalents during the period	\$ 7,703	\$ 4,926
Net income during the period	\$ 5,272	\$ 3,775
Net cash provided by operations during the period	\$ 9,095	\$ 5,948
Number of days of sales outstanding at start of period	104	114
Number of days of sales outstanding at end of period	104	106

The Company's principal source of cash was cash provided by operations. The Company was able to generate operating cash flows significantly in excess of net income in the quarter ended December 31, 2002 primarily as a result of net income and an increase in cash provided by growth in deferred revenue. Provided turnover of accounts receivable and revenues and profitability remain consistent with the quarter

ended December 31, 2002, the Company anticipates being able to continue to generate cash from operations primarily from the net income of the Company.

Cash and cash equivalents increased \$7,703,000 between March 31, 2002 and December 31, 2002 primarily as a result of cash provided by operating activities. Cash and cash equivalents increased approximately \$4,926,000 during the nine months ended December 30, 2001, also primarily as a result of cash generated by operating activities. Also, during the nine months ended December 31, 2002, the Company liquidated approximately \$255,000 in short-term equity investments, and moved those funds into cash and cash equivalent accounts.

Net cash used in investing activities for the nine months ended December 31, 2002 and 2001 was \$1,649,000 and \$1,383,000 respectively. Net cash used in investing activities for the nine months ended December 31, 2002 consisted of additions to equipment and improvements and capitalized software and was partially offset by the proceeds from the sale of short term investments. Net cash used in investing activities for the nine months ended December 31, 2001 consisted of additions to equipment and improvements and capitalized software. Management currently anticipates that additions to equipment and improvements for fiscal 2003 will be in excess of expenditures made during fiscal 2002 due to the relocation of the Company's principal administrative offices in California and the relocation of the company's principal office of the Company's NextGen division.

As of December 31, 2002, the Company had cash and cash equivalents of \$33.1 million. Except for the Company's intention to expend funds for the development of complementary products to its existing product line, new versions of certain of its products for the client-server environment to take advantage of more powerful technologies and to enable a more seamless integration of the Company's products, and certain investments in furniture, fixtures, and equipment related to its relocation to new facilities in California and Pennsylvania, the Company has no other significant capital commitments at this time.

The Company believes that its cash and cash equivalents on hand at December 31, 2002, together with cash flows from operations, if any, will be sufficient to meet its working capital and capital expenditure requirements for the balance of fiscal 2003.

Item 3. *Qualitative and Quantitative Disclosures About Market Risk*

The Company has a significant amount of cash and short-term investments with maturities less than three months. This cash portfolio exposes the Company to interest rate risk as short-term investment rates can be volatile. Given the short-term maturity structure of the Company's investment portfolio, the Company believes that it is not subject to principal fluctuations and the effective interest rate of the Company's portfolio tracks closely to various short-term money market interest rate benchmarks.

Item 4. *Controls and Proceedings*

The Company's Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively) have concluded, based on their evaluation as of February 12, 2003 ("Evaluation Date"), that the design and operation of the Company's "disclosure controls and procedures" (as defined in Rules 13a-14(c) and 15d-14(c) under the Securities Exchange Act of 1934, as amended ("Exchange Act")) are effective to ensure that information required to be disclosed by the Company in the reports filed or submitted by the Company under the Exchange Act is accumulated, recorded, processed, summarized and reported to its management, including the Company's principal executive officer and its principal financial officer, as appropriate to allow timely decisions regarding whether or not disclosure is required.

There were no significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the Evaluation Date, nor were there any significant deficiencies or material weaknesses in our internal controls. As a result, no corrective actions were required or undertaken.

There were no significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the Evaluation Date, including any corrective actions with regard to significant deficiencies and material weaknesses.

PART II – OTHER INFORMATION

Item 1. *Legal Proceedings.*

On April 22, 1997, a purported class action entitled JOHN P. CAVENY v. QUALITY SYSTEMS, INC., ET AL. was filed in the Superior Court of the State of California for the County of Orange, in which Mr. Caveny, on behalf of himself and all others who purchased the Company's Common Stock between June 26, 1995 and July 3, 1996, alleges that the Company, and Sheldon Razin, Robert J. Beck, Gregory S. Flynn, Abe C. LaLande, Donn Neufeld, Irma G. Carmona, John A. Bowers, Graeme H. Frehner, and Gordon L. Setran (all of the foregoing individuals were either officers, directors or both during the period from June 26, 1995 through July 3, 1996), as well as other defendants not affiliated with the Company, violated California Corporations Code Sections 25400 and 25500, California Civil Code Sections 1709 and 1710, and California Business and Professions Code Sections 17200 et. seq., by issuing positive statements about the Company that allegedly were knowingly false, in part, in order to assist the Company and the individual defendants in selling Common Stock at an inflated price in the Company's March 5, 1996 public offering and at other points during the class period. The complaint seeks compensatory and punitive damages in unspecified amounts, disgorgement, declaratory and injunctive relief, and attorneys' fees.

The Company and the other named defendants successfully demurred to the plaintiffs' claim under California Civil Code Sections 1709 and 1710, and that claim, which served as the only basis for plaintiffs' request for punitive damages, has been dismissed from both actions.

On January 25, 1999, the court denied plaintiffs' motion to certify the class representative and class legal counsel. Plaintiffs appealed that decision as to class legal counsel. On February 25, 2000, the Fourth District Court of Appeals affirmed the order disqualifying the class legal counsel. On May 9, 2000, the Court of Appeals issued its Remittur certifying its decision as final.

In May 2000, plaintiffs associated in additional class legal counsel, moved for approval by the court. Upon defendants' objection, the court on August 17, 2000, denied plaintiffs' motion, and ordered plaintiffs to retain new class counsel.

At the end of November 2000, the plaintiffs retained new class counsel who substituted in for plaintiffs' previous class counsel. The Company and the other named defendants did not oppose plaintiffs' motion for approval of the new class counsel. On January 24, 2001, the court granted the motion to certify class legal counsel.

On March 27, 2001, the court approved a notice of class certification to be mailed to shareholders who are potential class members. Between April 9, 2001 and May 9, 2001, class notice was mailed to potential class members.

In March 2002, defendant Graeme H. Frehner and certain other defendants not affiliated with the Company were dismissed from the action with prejudice by stipulated order.

On November 18, 2002, the parties reached an agreement to settle the consolidated action. On January 14, 2003, the court granted preliminary approval of the settlement, and approved a notice of the settlement to be mailed to shareholders who are potential class members. Shareholders who have not already requested exclusion from the class will have until March 28, 2003 to request exclusion from or opt out of the proposed settlement. The hearing for final approval of the settlement is scheduled for April 14, 2003. Upon the court's final approval of the settlement, the consolidated action will be dismissed

with prejudice as to all defendants. The settlement agreement expressly provides that Quality Systems and the named defendants do not admit, and continue to deny, any and all allegations of wrongdoing.

On May 14, 1997, a second purported class action entitled WENDY WOO v. QUALITY SYSTEMS, INC., ET AL. was filed in the same court, essentially repeating the allegations in the Caveny lawsuit and seeking identical relief. This action has for all purposes been consolidated with the Caveny action.

On July 1, 1997, a third purported class action was filed in the United States District Court repeating essentially the same factual allegations as the April 22, 1997 suit and purports to state claims under the Federal securities laws. By court order dated August 13, 1997, this action was stayed temporarily and the Court reserved jurisdiction to list the stay after all matters are final in the class action filed on April 22, 1997. The Company and its named officers and directors deny all allegations of wrongdoing made against them in these suits, consider the allegations groundless and without merit, and intend to vigorously defend against these actions.

The Company is a party to various other legal proceedings incidental to its business, none of which are considered by the Company to be material.

Item 2. *Changes in Securities and Use of Proceeds.*

None.

Item 3. *Defaults Upon Senior Securities.*

None.

Item 4. *Submissions of Matters to a Vote of Securities Holders.*

None

Item 5. *Other Information.*

None.

Item 6. *Exhibits and Reports on Form 8-K.*

Exhibits:

99.1 Officers' Certification

Reports on Form 8-K:

None.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

QUALITY SYSTEMS, INC.

Date: February 13, 2003

By: /s/ LOUIS SILVERMAN
Louis Silverman
Chief Executive Officer

Date: February 13, 2003

By: /s/ PAUL HOLT
Paul Holt
Chief Financial Officer; Principal Accounting Officer

EXHIBIT 99.1

**CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the quarterly report on Form 10-Q of Quality Systems, Inc. (the “Company”) for the quarterly period ended December 31, 2002 (the “Report”), the undersigned hereby certifies in his capacity as Chief Executive Officer of the Company, pursuant to 18 U.S.C. section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 13, 2003

By: /s/ LOUIS SILVERMAN
Louis Silverman
Chief Executive Officer

In connection with the quarterly report on Form 10-Q of Quality Systems, Inc. (the “Company”) for the quarterly period ended December 31, 2002 (the “Report”), the undersigned hereby certifies in his capacity as Chief Financial Officer of the Company, pursuant to 18 U.S.C. section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 13, 2003

By: /s/ PAUL HOLT
Paul Holt
Chief Financial Officer

I, Louis Silverman, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Quality Systems, Inc.;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
 - a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
 - b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and
 - c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;
5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
 - a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and
6. The registrant's other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Date: February 13, 2003

/s/ LOU SILVERMAN

Louis Silverman,
Chief Executive Officer

I, Paul Holt, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Quality Systems, Inc.;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
 - a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
 - b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and
 - c) presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures based on our evaluation as of the Evaluation Date;
5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
 - a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant's ability to record, process, summarize and report financial data and have identified for the registrant's auditors any material weaknesses in internal controls; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls; and
6. The registrant's other certifying officers and I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

Date: February 13, 2003

/s/ PAUL HOLT

Paul Holt
Chief Financial Officer